Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Kynexis Initiates Phase 1 Study Of KYN-5356 for Cognitive Impairment in Schizophrenia
Details : KYN-5356 is a clinical-stage small molecule targeting KAT-II in the kynurenine pathway. It is being evaluated in Phase 1 for cognitive impairment associated with schizophrenia.
Brand Name : KYN-5356
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2024
Lead Product(s) : KYN-5356
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Forbion
Deal Size : $62.1 million
Deal Type : Series A Financing
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
Details : Through the proceeds, Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.
Brand Name : KYN-5356
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 07, 2023
Lead Product(s) : KYN-5356
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Forbion
Deal Size : $62.1 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?
Reset All
